AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00254800
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00254748
- Locations
- 🇳🇱
Research Site, Veghel, Netherlands
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00254254
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Safety and Efficacy of Seroquel in First Episode Schizophrenia
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00254241
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of CP-675,206 in Refractory Melanoma
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 251
- Registration Number
- NCT00254579
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
🇺🇸Pfizer Investigational Site, Columbus, Ohio, United States
GALLANT 2 Tesaglitazar vs. Placebo
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00252772
- Locations
- 🇫🇮
Research Site, Ödet, Finland
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00252811
- Locations
- 🇮🇹
Research Site, Milan, Italy
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00252824
- Locations
- 🇸🇮
Research Site, Nova Gorica, Slovenia
🇭🇷Researh Site, Dubrovnik, Croatia
Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 340
- Registration Number
- NCT00252785
- Locations
- 🇯🇵
Research Site, Toyama, Japan
Diabetic Retinopathy Candesartan Trials
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5238
- Registration Number
- NCT00252733
- Locations
- 🇩🇰
Research Site, Odense, Denmark
© Copyright 2024. All Rights Reserved by MedPath